NEW YORK (GenomeWeb News) – Pfizer has tapped Cellartis to help it develop an in vitro screening model for predicting toxicity of new chemical entities in humans.
 
Cellartis said Tuesday that the collaboration gives Pfizer access to its human Embryonic Stem cell technology to develop the screening system, for which Cellartis will receive an upfront fee and research funding, and it will hold the rights to sub-license, use, and sell the toxicity screening model.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.